nodes	percent_of_prediction	percent_of_DWPC	metapath
Losartan—SLCO1B3—Methotrexate—lymphatic system cancer	0.0935	0.128	CbGbCtD
Losartan—CYP1A2—Carmustine—lymphatic system cancer	0.091	0.125	CbGbCtD
Losartan—CYP3A5—Teniposide—lymphatic system cancer	0.0822	0.113	CbGbCtD
Losartan—CYP2C19—Teniposide—lymphatic system cancer	0.0663	0.0911	CbGbCtD
Losartan—CYP2C9—Teniposide—lymphatic system cancer	0.0551	0.0757	CbGbCtD
Losartan—SLCO1B1—Methotrexate—lymphatic system cancer	0.0544	0.0747	CbGbCtD
Losartan—CYP3A5—Vincristine—lymphatic system cancer	0.0396	0.0543	CbGbCtD
Losartan—ABCB1—Mitoxantrone—lymphatic system cancer	0.0374	0.0514	CbGbCtD
Losartan—SLC22A6—Methotrexate—lymphatic system cancer	0.035	0.0481	CbGbCtD
Losartan—CYP3A4—Cytarabine—lymphatic system cancer	0.0325	0.0447	CbGbCtD
Losartan—CYP3A4—Teniposide—lymphatic system cancer	0.0321	0.044	CbGbCtD
Losartan—ALB—Methotrexate—lymphatic system cancer	0.0298	0.0409	CbGbCtD
Losartan—ABCB1—Vincristine—lymphatic system cancer	0.0258	0.0354	CbGbCtD
Losartan—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0224	0.0308	CbGbCtD
Losartan—ABCB1—Methotrexate—lymphatic system cancer	0.0156	0.0214	CbGbCtD
Losartan—CYP3A4—Vincristine—lymphatic system cancer	0.0154	0.0212	CbGbCtD
Losartan—Hypersensitivity—Teniposide—lymphatic system cancer	0.000607	0.00223	CcSEcCtD
Losartan—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000607	0.00223	CcSEcCtD
Losartan—Flushing—Carmustine—lymphatic system cancer	0.000606	0.00223	CcSEcCtD
Losartan—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000604	0.00222	CcSEcCtD
Losartan—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000602	0.00222	CcSEcCtD
Losartan—Anaemia—Bleomycin—lymphatic system cancer	0.000601	0.00221	CcSEcCtD
Losartan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000597	0.0022	CcSEcCtD
Losartan—Asthenia—Teniposide—lymphatic system cancer	0.000591	0.00218	CcSEcCtD
Losartan—Malaise—Bleomycin—lymphatic system cancer	0.000587	0.00216	CcSEcCtD
Losartan—Pruritus—Teniposide—lymphatic system cancer	0.000583	0.00215	CcSEcCtD
Losartan—Arrhythmia—Carmustine—lymphatic system cancer	0.000583	0.00215	CcSEcCtD
Losartan—Leukopenia—Bleomycin—lymphatic system cancer	0.000582	0.00214	CcSEcCtD
Losartan—Alopecia—Carmustine—lymphatic system cancer	0.000577	0.00212	CcSEcCtD
Losartan—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000575	0.00211	CcSEcCtD
Losartan—Body temperature increased—Fludarabine—lymphatic system cancer	0.000573	0.00211	CcSEcCtD
Losartan—Erythema—Carmustine—lymphatic system cancer	0.000568	0.00209	CcSEcCtD
Losartan—Cough—Bleomycin—lymphatic system cancer	0.000568	0.00209	CcSEcCtD
Losartan—Angiopathy—Vincristine—lymphatic system cancer	0.000565	0.00208	CcSEcCtD
Losartan—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000565	0.00208	CcSEcCtD
Losartan—Diarrhoea—Teniposide—lymphatic system cancer	0.000564	0.00208	CcSEcCtD
Losartan—Chest pain—Bleomycin—lymphatic system cancer	0.000554	0.00204	CcSEcCtD
Losartan—Myalgia—Bleomycin—lymphatic system cancer	0.000554	0.00204	CcSEcCtD
Losartan—Alopecia—Vincristine—lymphatic system cancer	0.00055	0.00203	CcSEcCtD
Losartan—Back pain—Carmustine—lymphatic system cancer	0.000549	0.00202	CcSEcCtD
Losartan—Discomfort—Bleomycin—lymphatic system cancer	0.000547	0.00201	CcSEcCtD
Losartan—Ecchymosis—Methotrexate—lymphatic system cancer	0.000544	0.002	CcSEcCtD
Losartan—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000542	0.00199	CcSEcCtD
Losartan—Alopecia—Mitoxantrone—lymphatic system cancer	0.000536	0.00197	CcSEcCtD
Losartan—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000536	0.00197	CcSEcCtD
Losartan—Confusional state—Bleomycin—lymphatic system cancer	0.000535	0.00197	CcSEcCtD
Losartan—Vision blurred—Carmustine—lymphatic system cancer	0.000535	0.00197	CcSEcCtD
Losartan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000534	0.00196	CcSEcCtD
Losartan—Tremor—Carmustine—lymphatic system cancer	0.000532	0.00196	CcSEcCtD
Losartan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000531	0.00195	CcSEcCtD
Losartan—Oedema—Bleomycin—lymphatic system cancer	0.000531	0.00195	CcSEcCtD
Losartan—Erythema—Mitoxantrone—lymphatic system cancer	0.000528	0.00194	CcSEcCtD
Losartan—Infection—Bleomycin—lymphatic system cancer	0.000528	0.00194	CcSEcCtD
Losartan—Anaemia—Carmustine—lymphatic system cancer	0.000525	0.00193	CcSEcCtD
Losartan—Back pain—Vincristine—lymphatic system cancer	0.000524	0.00193	CcSEcCtD
Losartan—Vomiting—Teniposide—lymphatic system cancer	0.000524	0.00193	CcSEcCtD
Losartan—Agitation—Carmustine—lymphatic system cancer	0.000522	0.00192	CcSEcCtD
Losartan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00052	0.00191	CcSEcCtD
Losartan—Asthenia—Fludarabine—lymphatic system cancer	0.00052	0.00191	CcSEcCtD
Losartan—Rash—Teniposide—lymphatic system cancer	0.00052	0.00191	CcSEcCtD
Losartan—Dermatitis—Teniposide—lymphatic system cancer	0.000519	0.00191	CcSEcCtD
Losartan—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000517	0.0019	CcSEcCtD
Losartan—Headache—Teniposide—lymphatic system cancer	0.000516	0.0019	CcSEcCtD
Losartan—Pruritus—Fludarabine—lymphatic system cancer	0.000512	0.00189	CcSEcCtD
Losartan—Back pain—Mitoxantrone—lymphatic system cancer	0.000511	0.00188	CcSEcCtD
Losartan—Leukopenia—Carmustine—lymphatic system cancer	0.000508	0.00187	CcSEcCtD
Losartan—Anorexia—Bleomycin—lymphatic system cancer	0.000506	0.00186	CcSEcCtD
Losartan—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000502	0.00185	CcSEcCtD
Losartan—Anaemia—Vincristine—lymphatic system cancer	0.000501	0.00184	CcSEcCtD
Losartan—Agitation—Vincristine—lymphatic system cancer	0.000498	0.00183	CcSEcCtD
Losartan—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000498	0.00183	CcSEcCtD
Losartan—Photosensitivity—Methotrexate—lymphatic system cancer	0.000497	0.00183	CcSEcCtD
Losartan—Hypotension—Bleomycin—lymphatic system cancer	0.000496	0.00183	CcSEcCtD
Losartan—Diarrhoea—Fludarabine—lymphatic system cancer	0.000496	0.00182	CcSEcCtD
Losartan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00049	0.0018	CcSEcCtD
Losartan—Nausea—Teniposide—lymphatic system cancer	0.000489	0.0018	CcSEcCtD
Losartan—Anaemia—Mitoxantrone—lymphatic system cancer	0.000488	0.0018	CcSEcCtD
Losartan—Vertigo—Vincristine—lymphatic system cancer	0.000487	0.00179	CcSEcCtD
Losartan—Leukopenia—Vincristine—lymphatic system cancer	0.000485	0.00179	CcSEcCtD
Losartan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000484	0.00178	CcSEcCtD
Losartan—Myalgia—Carmustine—lymphatic system cancer	0.000484	0.00178	CcSEcCtD
Losartan—Chest pain—Carmustine—lymphatic system cancer	0.000484	0.00178	CcSEcCtD
Losartan—Anxiety—Carmustine—lymphatic system cancer	0.000482	0.00177	CcSEcCtD
Losartan—Paraesthesia—Bleomycin—lymphatic system cancer	0.000477	0.00175	CcSEcCtD
Losartan—Malaise—Mitoxantrone—lymphatic system cancer	0.000476	0.00175	CcSEcCtD
Losartan—Dyspnoea—Bleomycin—lymphatic system cancer	0.000473	0.00174	CcSEcCtD
Losartan—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000473	0.00174	CcSEcCtD
Losartan—Confusional state—Carmustine—lymphatic system cancer	0.000467	0.00172	CcSEcCtD
Losartan—Oedema—Carmustine—lymphatic system cancer	0.000464	0.00171	CcSEcCtD
Losartan—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000463	0.0017	CcSEcCtD
Losartan—Decreased appetite—Bleomycin—lymphatic system cancer	0.000462	0.0017	CcSEcCtD
Losartan—Myalgia—Vincristine—lymphatic system cancer	0.000462	0.0017	CcSEcCtD
Losartan—Cough—Mitoxantrone—lymphatic system cancer	0.000461	0.0017	CcSEcCtD
Losartan—Infection—Carmustine—lymphatic system cancer	0.000461	0.00169	CcSEcCtD
Losartan—Vomiting—Fludarabine—lymphatic system cancer	0.000461	0.00169	CcSEcCtD
Losartan—Rash—Fludarabine—lymphatic system cancer	0.000457	0.00168	CcSEcCtD
Losartan—Dermatitis—Fludarabine—lymphatic system cancer	0.000456	0.00168	CcSEcCtD
Losartan—Pain—Bleomycin—lymphatic system cancer	0.000454	0.00167	CcSEcCtD
Losartan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000454	0.00167	CcSEcCtD
Losartan—Headache—Fludarabine—lymphatic system cancer	0.000454	0.00167	CcSEcCtD
Losartan—Tachycardia—Carmustine—lymphatic system cancer	0.000452	0.00166	CcSEcCtD
Losartan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00045	0.00165	CcSEcCtD
Losartan—Myalgia—Mitoxantrone—lymphatic system cancer	0.00045	0.00165	CcSEcCtD
Losartan—Chest pain—Mitoxantrone—lymphatic system cancer	0.00045	0.00165	CcSEcCtD
Losartan—Anxiety—Mitoxantrone—lymphatic system cancer	0.000448	0.00165	CcSEcCtD
Losartan—Discomfort—Mitoxantrone—lymphatic system cancer	0.000444	0.00163	CcSEcCtD
Losartan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000442	0.00163	CcSEcCtD
Losartan—Oedema—Vincristine—lymphatic system cancer	0.000442	0.00163	CcSEcCtD
Losartan—Anorexia—Carmustine—lymphatic system cancer	0.000442	0.00163	CcSEcCtD
Losartan—Infection—Vincristine—lymphatic system cancer	0.00044	0.00162	CcSEcCtD
Losartan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000438	0.00161	CcSEcCtD
Losartan—Confusional state—Mitoxantrone—lymphatic system cancer	0.000435	0.0016	CcSEcCtD
Losartan—Nervous system disorder—Vincristine—lymphatic system cancer	0.000434	0.0016	CcSEcCtD
Losartan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000433	0.00159	CcSEcCtD
Losartan—Hypotension—Carmustine—lymphatic system cancer	0.000433	0.00159	CcSEcCtD
Losartan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000431	0.00159	CcSEcCtD
Losartan—Oedema—Mitoxantrone—lymphatic system cancer	0.000431	0.00159	CcSEcCtD
Losartan—Nausea—Fludarabine—lymphatic system cancer	0.00043	0.00158	CcSEcCtD
Losartan—Infection—Mitoxantrone—lymphatic system cancer	0.000428	0.00158	CcSEcCtD
Losartan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000428	0.00157	CcSEcCtD
Losartan—Shock—Mitoxantrone—lymphatic system cancer	0.000424	0.00156	CcSEcCtD
Losartan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000422	0.00155	CcSEcCtD
Losartan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000422	0.00155	CcSEcCtD
Losartan—Urticaria—Bleomycin—lymphatic system cancer	0.000422	0.00155	CcSEcCtD
Losartan—Anorexia—Vincristine—lymphatic system cancer	0.000422	0.00155	CcSEcCtD
Losartan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000421	0.00155	CcSEcCtD
Losartan—Body temperature increased—Bleomycin—lymphatic system cancer	0.00042	0.00154	CcSEcCtD
Losartan—Insomnia—Carmustine—lymphatic system cancer	0.000419	0.00154	CcSEcCtD
Losartan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000417	0.00153	CcSEcCtD
Losartan—Paraesthesia—Carmustine—lymphatic system cancer	0.000416	0.00153	CcSEcCtD
Losartan—Hypotension—Vincristine—lymphatic system cancer	0.000413	0.00152	CcSEcCtD
Losartan—Dyspnoea—Carmustine—lymphatic system cancer	0.000413	0.00152	CcSEcCtD
Losartan—Somnolence—Carmustine—lymphatic system cancer	0.000412	0.00152	CcSEcCtD
Losartan—Anorexia—Mitoxantrone—lymphatic system cancer	0.000411	0.00151	CcSEcCtD
Losartan—Ataxia—Methotrexate—lymphatic system cancer	0.000411	0.00151	CcSEcCtD
Losartan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000403	0.00148	CcSEcCtD
Losartan—Decreased appetite—Carmustine—lymphatic system cancer	0.000403	0.00148	CcSEcCtD
Losartan—Hypotension—Mitoxantrone—lymphatic system cancer	0.000403	0.00148	CcSEcCtD
Losartan—Insomnia—Vincristine—lymphatic system cancer	0.0004	0.00147	CcSEcCtD
Losartan—Paraesthesia—Vincristine—lymphatic system cancer	0.000397	0.00146	CcSEcCtD
Losartan—Pain—Carmustine—lymphatic system cancer	0.000396	0.00146	CcSEcCtD
Losartan—Constipation—Carmustine—lymphatic system cancer	0.000396	0.00146	CcSEcCtD
Losartan—Breast disorder—Methotrexate—lymphatic system cancer	0.000395	0.00145	CcSEcCtD
Losartan—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000393	0.00145	CcSEcCtD
Losartan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000393	0.00144	CcSEcCtD
Losartan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000391	0.00144	CcSEcCtD
Losartan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000387	0.00142	CcSEcCtD
Losartan—Decreased appetite—Vincristine—lymphatic system cancer	0.000385	0.00142	CcSEcCtD
Losartan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000384	0.00141	CcSEcCtD
Losartan—Somnolence—Mitoxantrone—lymphatic system cancer	0.000383	0.00141	CcSEcCtD
Losartan—Feeling abnormal—Carmustine—lymphatic system cancer	0.000382	0.00141	CcSEcCtD
Losartan—Fatigue—Vincristine—lymphatic system cancer	0.000381	0.0014	CcSEcCtD
Losartan—Asthenia—Bleomycin—lymphatic system cancer	0.000381	0.0014	CcSEcCtD
Losartan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000379	0.0014	CcSEcCtD
Losartan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000379	0.00139	CcSEcCtD
Losartan—Pain—Vincristine—lymphatic system cancer	0.000378	0.00139	CcSEcCtD
Losartan—Constipation—Vincristine—lymphatic system cancer	0.000378	0.00139	CcSEcCtD
Losartan—Pruritus—Bleomycin—lymphatic system cancer	0.000376	0.00138	CcSEcCtD
Losartan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000375	0.00138	CcSEcCtD
Losartan—Eosinophilia—Methotrexate—lymphatic system cancer	0.000374	0.00138	CcSEcCtD
Losartan—Fatigue—Mitoxantrone—lymphatic system cancer	0.000372	0.00137	CcSEcCtD
Losartan—Pancreatitis—Methotrexate—lymphatic system cancer	0.00037	0.00136	CcSEcCtD
Losartan—Pain—Mitoxantrone—lymphatic system cancer	0.000369	0.00136	CcSEcCtD
Losartan—Constipation—Mitoxantrone—lymphatic system cancer	0.000369	0.00136	CcSEcCtD
Losartan—Abdominal pain—Carmustine—lymphatic system cancer	0.000366	0.00135	CcSEcCtD
Losartan—Body temperature increased—Carmustine—lymphatic system cancer	0.000366	0.00135	CcSEcCtD
Losartan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000362	0.00133	CcSEcCtD
Losartan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000355	0.00131	CcSEcCtD
Losartan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000352	0.0013	CcSEcCtD
Losartan—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000351	0.00129	CcSEcCtD
Losartan—Abdominal pain—Vincristine—lymphatic system cancer	0.00035	0.00129	CcSEcCtD
Losartan—Body temperature increased—Vincristine—lymphatic system cancer	0.00035	0.00129	CcSEcCtD
Losartan—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000348	0.00128	CcSEcCtD
Losartan—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000345	0.00127	CcSEcCtD
Losartan—Urticaria—Mitoxantrone—lymphatic system cancer	0.000342	0.00126	CcSEcCtD
Losartan—Hypersensitivity—Carmustine—lymphatic system cancer	0.000342	0.00126	CcSEcCtD
Losartan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000341	0.00125	CcSEcCtD
Losartan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000341	0.00125	CcSEcCtD
Losartan—Pneumonia—Methotrexate—lymphatic system cancer	0.000339	0.00125	CcSEcCtD
Losartan—Vomiting—Bleomycin—lymphatic system cancer	0.000338	0.00124	CcSEcCtD
Losartan—Rash—Bleomycin—lymphatic system cancer	0.000335	0.00123	CcSEcCtD
Losartan—Dermatitis—Bleomycin—lymphatic system cancer	0.000335	0.00123	CcSEcCtD
Losartan—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000334	0.00123	CcSEcCtD
Losartan—Asthenia—Carmustine—lymphatic system cancer	0.000333	0.00122	CcSEcCtD
Losartan—Renal failure—Methotrexate—lymphatic system cancer	0.000331	0.00122	CcSEcCtD
Losartan—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000327	0.0012	CcSEcCtD
Losartan—Hypersensitivity—Vincristine—lymphatic system cancer	0.000326	0.0012	CcSEcCtD
Losartan—Sweating—Methotrexate—lymphatic system cancer	0.000323	0.00119	CcSEcCtD
Losartan—Epistaxis—Methotrexate—lymphatic system cancer	0.000318	0.00117	CcSEcCtD
Losartan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000317	0.00117	CcSEcCtD
Losartan—Asthenia—Vincristine—lymphatic system cancer	0.000317	0.00117	CcSEcCtD
Losartan—Diarrhoea—Carmustine—lymphatic system cancer	0.000317	0.00117	CcSEcCtD
Losartan—Nausea—Bleomycin—lymphatic system cancer	0.000315	0.00116	CcSEcCtD
Losartan—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000314	0.00116	CcSEcCtD
Losartan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000309	0.00114	CcSEcCtD
Losartan—Dizziness—Carmustine—lymphatic system cancer	0.000307	0.00113	CcSEcCtD
Losartan—Diarrhoea—Vincristine—lymphatic system cancer	0.000303	0.00111	CcSEcCtD
Losartan—Hepatitis—Methotrexate—lymphatic system cancer	0.000302	0.00111	CcSEcCtD
Losartan—Pharyngitis—Methotrexate—lymphatic system cancer	0.0003	0.0011	CcSEcCtD
Losartan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000295	0.00109	CcSEcCtD
Losartan—Vomiting—Carmustine—lymphatic system cancer	0.000295	0.00108	CcSEcCtD
Losartan—Dizziness—Vincristine—lymphatic system cancer	0.000293	0.00108	CcSEcCtD
Losartan—Rash—Carmustine—lymphatic system cancer	0.000292	0.00108	CcSEcCtD
Losartan—Dermatitis—Carmustine—lymphatic system cancer	0.000292	0.00107	CcSEcCtD
Losartan—Headache—Carmustine—lymphatic system cancer	0.00029	0.00107	CcSEcCtD
Losartan—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000286	0.00105	CcSEcCtD
Losartan—Tinnitus—Methotrexate—lymphatic system cancer	0.000282	0.00104	CcSEcCtD
Losartan—Vomiting—Vincristine—lymphatic system cancer	0.000281	0.00104	CcSEcCtD
Losartan—Rash—Vincristine—lymphatic system cancer	0.000279	0.00103	CcSEcCtD
Losartan—Dermatitis—Vincristine—lymphatic system cancer	0.000279	0.00103	CcSEcCtD
Losartan—Headache—Vincristine—lymphatic system cancer	0.000277	0.00102	CcSEcCtD
Losartan—Nausea—Carmustine—lymphatic system cancer	0.000275	0.00101	CcSEcCtD
Losartan—Angiopathy—Methotrexate—lymphatic system cancer	0.000274	0.00101	CcSEcCtD
Losartan—Vomiting—Mitoxantrone—lymphatic system cancer	0.000274	0.00101	CcSEcCtD
Losartan—Rash—Mitoxantrone—lymphatic system cancer	0.000272	0.001	CcSEcCtD
Losartan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000271	0.000999	CcSEcCtD
Losartan—Headache—Mitoxantrone—lymphatic system cancer	0.00027	0.000994	CcSEcCtD
Losartan—Alopecia—Methotrexate—lymphatic system cancer	0.000267	0.000983	CcSEcCtD
Losartan—Erythema—Methotrexate—lymphatic system cancer	0.000263	0.000968	CcSEcCtD
Losartan—Nausea—Vincristine—lymphatic system cancer	0.000263	0.000967	CcSEcCtD
Losartan—Dysgeusia—Methotrexate—lymphatic system cancer	0.000258	0.000948	CcSEcCtD
Losartan—Nausea—Mitoxantrone—lymphatic system cancer	0.000256	0.000942	CcSEcCtD
Losartan—Back pain—Methotrexate—lymphatic system cancer	0.000254	0.000936	CcSEcCtD
Losartan—Vision blurred—Methotrexate—lymphatic system cancer	0.000248	0.000912	CcSEcCtD
Losartan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000244	0.000898	CcSEcCtD
Losartan—Anaemia—Methotrexate—lymphatic system cancer	0.000243	0.000895	CcSEcCtD
Losartan—Malaise—Methotrexate—lymphatic system cancer	0.000237	0.000873	CcSEcCtD
Losartan—Vertigo—Methotrexate—lymphatic system cancer	0.000236	0.00087	CcSEcCtD
Losartan—Leukopenia—Methotrexate—lymphatic system cancer	0.000235	0.000867	CcSEcCtD
Losartan—Cough—Methotrexate—lymphatic system cancer	0.00023	0.000845	CcSEcCtD
Losartan—Myalgia—Methotrexate—lymphatic system cancer	0.000224	0.000824	CcSEcCtD
Losartan—Arthralgia—Methotrexate—lymphatic system cancer	0.000224	0.000824	CcSEcCtD
Losartan—Chest pain—Methotrexate—lymphatic system cancer	0.000224	0.000824	CcSEcCtD
Losartan—Discomfort—Methotrexate—lymphatic system cancer	0.000221	0.000814	CcSEcCtD
Losartan—Confusional state—Methotrexate—lymphatic system cancer	0.000216	0.000797	CcSEcCtD
Losartan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000215	0.00079	CcSEcCtD
Losartan—Infection—Methotrexate—lymphatic system cancer	0.000213	0.000785	CcSEcCtD
Losartan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000211	0.000775	CcSEcCtD
Losartan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00021	0.000774	CcSEcCtD
Losartan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000208	0.000764	CcSEcCtD
Losartan—Anorexia—Methotrexate—lymphatic system cancer	0.000205	0.000753	CcSEcCtD
Losartan—Hypotension—Methotrexate—lymphatic system cancer	0.000201	0.000738	CcSEcCtD
Losartan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000196	0.00072	CcSEcCtD
Losartan—Insomnia—Methotrexate—lymphatic system cancer	0.000194	0.000715	CcSEcCtD
Losartan—Paraesthesia—Methotrexate—lymphatic system cancer	0.000193	0.00071	CcSEcCtD
Losartan—Dyspnoea—Methotrexate—lymphatic system cancer	0.000191	0.000704	CcSEcCtD
Losartan—Somnolence—Methotrexate—lymphatic system cancer	0.000191	0.000702	CcSEcCtD
Losartan—Dyspepsia—Methotrexate—lymphatic system cancer	0.000189	0.000696	CcSEcCtD
Losartan—Decreased appetite—Methotrexate—lymphatic system cancer	0.000187	0.000687	CcSEcCtD
Losartan—Fatigue—Methotrexate—lymphatic system cancer	0.000185	0.000681	CcSEcCtD
Losartan—Pain—Methotrexate—lymphatic system cancer	0.000184	0.000676	CcSEcCtD
Losartan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000177	0.000651	CcSEcCtD
Losartan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000176	0.000646	CcSEcCtD
Losartan—Urticaria—Methotrexate—lymphatic system cancer	0.000171	0.000628	CcSEcCtD
Losartan—Body temperature increased—Methotrexate—lymphatic system cancer	0.00017	0.000625	CcSEcCtD
Losartan—Abdominal pain—Methotrexate—lymphatic system cancer	0.00017	0.000625	CcSEcCtD
Losartan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000158	0.000582	CcSEcCtD
Losartan—Asthenia—Methotrexate—lymphatic system cancer	0.000154	0.000567	CcSEcCtD
Losartan—Pruritus—Methotrexate—lymphatic system cancer	0.000152	0.000559	CcSEcCtD
Losartan—Diarrhoea—Methotrexate—lymphatic system cancer	0.000147	0.000541	CcSEcCtD
Losartan—Dizziness—Methotrexate—lymphatic system cancer	0.000142	0.000523	CcSEcCtD
Losartan—Vomiting—Methotrexate—lymphatic system cancer	0.000137	0.000502	CcSEcCtD
Losartan—Rash—Methotrexate—lymphatic system cancer	0.000135	0.000498	CcSEcCtD
Losartan—Dermatitis—Methotrexate—lymphatic system cancer	0.000135	0.000498	CcSEcCtD
Losartan—Headache—Methotrexate—lymphatic system cancer	0.000135	0.000495	CcSEcCtD
Losartan—Nausea—Methotrexate—lymphatic system cancer	0.000128	0.000469	CcSEcCtD
